Numotion Launches ATOM Outcome Measures Program

Numotion has launched the Assistive Technology Outcome Measure (ATOM) program as a way to gauge the effectiveness of Complex Rehab Technology (CRT) from the perspectives of the people who use it.

Numotion’s Training and Education division will manage the program with Georgia Institute of Technology, according to a news announcement.

Numotion’s team of ATPs or the clinicians they work with aim to administer the ATOM three times per adult client: First during the initial evaluation, then one month after equipment delivery and six months after equipment delivery. At this time, clients being targeted for the survey are those who are over 18 years old and who are being evaluated for a second wheelchair or who are currently ambulatory, but who need assistive technology for functional ambulation.

Data collected from ATOM surveys, Numotion said, will be used in multiple ways, such as to identify areas to focus on during seating and mobility evaluations; to better educate clients on reimbursement policies and issues; to compare client satisfaction and functional outcomes using in-person evaluations versus telehealth evaluations; and “quantifying the effectiveness of assistive technology in helping users achieve greater independence and health.”

Initial results and insights should be available starting in early 2021, Numotion added.

John Pryles, Numotion’s Executive VP of Sales who also oversees the development of the provider’s ATPs, said, “ATOM is a high-quality outcome measure. As the largest provider of CRT in the country, we expect to collect a clinically meaningful number of responses in a short period of time, which is generally difficult to come by in a niche focus area like CRT. The data and information being collected is critical to end users, providers and clinicians and will help to shape interventions with individuals with complex mobility needs.”

About the Author

Laurie Watanabe is the editor of Mobility Management. She can be reached at lwatanabe@1105media.com.